Ms. Susan Chia brings close to 20 years of experience in pharmaceutical and healthcare industry, having held positions in sales and clinical research with Glaxo Wellcome (now GSK), Johnson and Johnson and Covance. Ms. Chia was one of the pioneers in the set up of Contract Research Organisation (CRO) in Singapore and Asia, before the company became a public listed company in NYSE as Covance. Over her 13 years with Covance, she served in various leadership positions, including Client Relationship Director, Administrative Head Singapore, and Director of Clinical Operations, Asia Pacific. In her last position as Director of Clinical Operations, she had responsibilities for Phase II to IV clinical trial management in 12 countries, including Australia, China, Korea and Southeast Asia. Ms. Chia holds a Bachelor of Science degree from the National University of Singapore, with major in Chemistry and Microbiology. She has also received a Gold Award for Graduate Diploma in Marketing from the Marketing Institute of Singapore.

Ms. Emily Cheung possesses more than 15 years of working experience at senior management level in the healthcare industry, with responsibility in strategic planning, directing and overseeing business operations. Prior to Invitrocue, Ms Cheung spent more than a decade at Cordlife, a public listed company in Singapore specialising in cord blood stem cells banking services and healthcare related services, where she was the CEO of the company’s Hong Kong division. With the growth of the business, she later served as Cordlife’s Director of Business Development, overseeing the development of new business opportunities in Hong Kong, Macau and the Philippines.

Ms. Katharina Bernlochner is a senior executive in the healthcare industry, with over 25 years of experience in German and international healthcare systems. As a provider of ideas with a focus on the implementation of new projects, she has established innovative interdisciplinary services in different sectors of medicine. She has also founded her own company for outpatient intensive care. Her career experience includes working for Doctors without Borders (Médecins Sans Frontières ) in Africa and Southeast Asia. Ms. Bernlochner holds a Master’s degree in Nursing Management from the University of Applied Sciences in Hamburg.

Mr. Martin Bach has more than 20 years of experience directing employees in multinational companies. Mr. Bach has led these companies through start-up, survival, turnaround and growth modes. He has spent decades in the medical industries. His understanding of both domestic and international businesses and global distribution channels encompasses manufacturing, wholesale, direct sales and joint ventures. Among his significant previous roles, he served as Managing Director of a German based healthcare and medical device company. An entrepreneur by heart, he then founded his own Company with a dedicated presence in Abu Dhabi, where he gained valuable knowledge on doing business and building relationships in the UAE regions. Mr. Bach holds a Master of Business Administration, International Marketing from the Berufsakademie in Ravensburg (Germany).

Dr Lindner is a senior executive with significant global experience across a range of industries including healthcare and technology. He was a founding partner of global healthcare company Medi-Globe, a supplier of equipment and services for minimally invasive surgery and urology, as well as hospital supplies. His experience also includes establishment of a private venture capital business, which invested across industries including technology, new media and internet. Most recently, Dr Lindner founded health complete GmbH, a material supply company specializing in highly efficient and biodegradable cleaning product. Dr Lindner has a PhD (Business) from Ludwig-Maximilian University of Munich.

Dr Steven Fang is Founder and Executive Director of Invitrocue Limited, partner at Clearbridge Accelerator and was the Group CEO of CordLife Ltd. He has been awarded with the World Economic Forum Technology Pioneer Award, Ernst & Young Entrepreneur of the Year for New Enterprise, Spirit of Enterprise and the Asia Pacific Entrepreneurship Award’s Outstanding Entrepreneur Award.

Dr Fang has over two decades of experience in building biotechnology and life sciences companies. Dr Fang was the Group CEO of CordLife Ltd, which he founded in May 2001; the company has since grown with operations in Singapore, Hong Kong, Jakarta, Indonesia, Kolkata, India, and Australia. CordLife was listed on the Australian Stock Exchange in 2004 and spun off a separate entity in 2012, which subsequently was listed on the Singapore Stock Exchange. Prior to CordLife, Dr Fang held various management positions in Becton Dickinson, Baxter Healthcare and Sterling Pharmaceuticals (now part of GSK).